0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Small Case Series |

Bilateral Superselective Ophthalmic Artery Chemotherapy for Bilateral Retinoblastoma: Tandem Therapy FREE

David H. Abramson, MD; Ira J. Dunkel, MD; Scott E. Brodie, MD, PhD; Brian Marr, MD; Y. Pierre Gobin, MD
[+] Author Affiliations

Author Affiliations: Ophthalmic Oncology Service (Drs Abramson and Marr), and Department of Pediatrics (Dr Dunkel), Memorial Sloan-Kettering Cancer Center; Department of Ophthalmology, Mt Sinai School of Medicine (Dr Brodie); and Division of Interventional Neuroradiology, Department of Radiology, Neurosurgery and Neurology, Weill Cornell Medical College (Dr Gobin), New York, New York.


Section Editor: W. Richard Green, MD

More Author Information
Arch Ophthalmol. 2010;128(3):370-372. doi:10.1001/archophthalmol.2010.7.
Text Size: A A A
Published online

We previously described our initial experience with superselective ophthalmic artery delivery of chemotherapy for advanced retinoblastoma and emphasized that it was both effective and safe for both the patient and eye.1,2 In each of those cases, only 1 eye was treated with this novel technique. We now report on the first 4 patients with advanced (Reese-Ellsworth group V) bilateral disease in whom initial management was bilateral treatment accomplished during the same treatment session.

REPORT OF CASES

Four children with bilateral Reese-Ellsworth group V retinoblastomas (4 with bilateral Vb, 1 with Vb in one eye and Va in the fellow eye; international classification, C:4, D:1, and E:3) were initially treated with a superselective arterial infusion (ophthalmic artery) of chemotherapy and were followed up every 3 to 4 weeks with examinations while under anesthesia. The chemotherapy was delivered to both eyes in the same session by first passing a catheter into 1 ophthalmic artery and infusing chemotherapy, retracting the catheter back to the aorta, and then extending it into the fellow carotid artery and up into the fellow ophthalmic artery (tandem therapy). Focal therapy with laser hyperthermia (transpupillary thermotherapy) to small tumors and cryotherapy to intermediate tumors was subsequently performed (Figure).

Place holder to copy figure label and caption
Figure.

Pretreatment and corresponding posttreatment fundus appearance. Transpupillary thermotherapy (TTT) laser and cryotherapy applications are listed for each eye.

Graphic Jump Location

There were 2 boys and 2 girls in the study group; their ages at treatment were 6 months, 5 months, 15 months, and 19 months. One child had a family history of retinoblastoma and all had bilateral disease at initial diagnosis. The macula was involved with the tumor in all cases. Pretreatment electroretinography (ERG) was performed on 6 of the 8 eyes; flicker potentials were 22.1 μV, 22.4 μV, 33.4 μV, 71.7 μV, and 105.5 μV, and “barely detectable” in 1 case. Follow-up ranged from 8 to 17 months (mean, 12.75 months), and 2 of the patients were followed up for more than 1 year. Melphalan was used alone in 2 patients and melphalan plus topotecan was used in 2 patients. Sessions were performed at 3- to 4-week intervals, and the total number of sessions ranged from 1 to 3 (mean, 2.5). One patient had only 1 session. No patient received external beam radiation or plaque therapy. The total doses of melphalan per tandem session (adding the dose from the right and left eyes) was 4 mg in 1 session, 5 mg in 8 sessions, and 5.5 mg in 1 session; for topotecan, doses were 0.3 mg in 3 sessions, 0.5 mg in 1 session, and 1 mg in 1 session. Topotecan was added for the eyes with more advanced disease.

All patients are alive and free of metastatic disease. No eye needed to undergo radiation or enucleation after intraarterial chemosurgery. There have been no intraoperative or postoperative vascular complications. No patient has received a port or transfusion of any type, required hospitalization, or developed fever/neutropenia. There have been no grade 4 events. One patient developed grade 3 neutropenia with each of 3 infusions of melphalan (total doses: 5, 5, and 4 mg).

All tumors and the vitreous seeds in each case showed significant reduction in size within 3 weeks of treatment. The most recent ERG results were classified as poor (0.2-25.0 μV), fair (25.1-50.0 μV), good (50.1-75.0 μV), and excellent (>75.0 μV). Of the 6 eyes having evaluable ERGs before treatment, the ERG results were poor in 1, fair in 3, good in 1, and excellent in 1. After all treatments, the ERG results improved in 3 eyes, stayed the same in 1 eye, and diminished in 2 eyes. Posttreatment ERGs were available for 8 eyes and were poor in 3, good in 1, and excellent in 4.

Pretreatment and final posttreatment RetCam (Clarity Medical Systems Inc, Pleasanton, California) photographs of each of the eyes are presented in the Figure. Some eyes had transpupillary thermotherapy laser or cryotherapy (for small tumors in the eye).

COMMENT

The concept of intraarterial chemotherapy for retinoblastoma was introduced by Reese et al3 more than 50 years ago. The alkylating agent triethylene melanamine was used via puncture sites in the carotid artery on the side of the eye to be treated. Reese et al reported good results in hundreds of eyes but other investigators (lead by A. Kaneko, MD)4,5 introduced selective chemotherapy for retinoblastoma. These investigators developed a catheter that is passed from the groin (femoral artery) into the carotid artery on the side to be treated. A balloon in the catheter is then inflated, occluding the carotid, and chemotherapy is infused proximal to the occlusion. Our technique involves superselective infusion directly into the ophthalmic artery. Unlike systemic chemotherapy for retinoblastoma, the technique has fewer systemic adverse effects; requires no port, hospitalizations, or transfusions; and may be curative alone. This study highlights the fact that now both eyes of the same patient can be treated with this technique during the same session of anesthesia, and despite the “double dose” of chemotherapy, there were no significant systemic adverse effects. The eyes experienced no significant adverse effects either and the ERG results actually improved in half of the eyes for which measurements were available before treatment. In 2 cases, the ERG results diminished after treatment (from fair to poor in one case and fair to flat in another). This child's ERG results did not diminish when only melphalan was used; when topotecan was added in the last session, the ERG results in both eyes decreased. We have subsequently changed the dose of topotecan and continue to use this agent without problems.

Bilateral intraarterial chemotherapy for bilateral retinoblastoma (tandem therapy), even when advanced (Reese-Ellsworth group V), appears to be safe for the patient and eye and can avoid the use of multiagent systemic chemotherapy, enucleation, and/or radiation in any form for children with bilateral Reese-Ellsworth V eyes. Our protocol for treatment began in May 2006, but longer follow-up is needed to see if any future complications will develop.

ARTICLE INFORMATION

Correspondence: Dr Abramson, Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, 70 E 66th St, New York, NY 10065 (abramsod@mskcc.org).

Financial Disclosure: None reported.

Funding/Support: This study was supported in part by a grant from The Fund for Ophthalmic Knowledge Inc.

REFERENCES

Abramson  DHDunkel  IJBrodie  SEKim  JWGobin  YP A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115 (8) 1398- 1404, 1404. e1
PubMed Link to Article
Brodie  SEPierre Gobin  YDunkel  IJKim  JWAbramson  DH Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol 2009;119 (1) 13- 22
PubMed Link to Article
Reese  ABHyman  GTapley  NForrest  AW The treatment of retinoblastoma by x-ray and triethylene melamine. AMA Arch Ophthalmol 1958;60 (5) 897- 906
PubMed Link to Article
Mohri  M The technique of selective ophthalmic arterial infusion for conservative treatment of recurrent retinoblastoma [in Japanese]. Keio J Med 1993;70679- 687
Yamane  TKaneko  AMohri  M The technique of ophthalmic artery infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004;9 (2) 69- 73
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure.

Pretreatment and corresponding posttreatment fundus appearance. Transpupillary thermotherapy (TTT) laser and cryotherapy applications are listed for each eye.

Graphic Jump Location

Tables

References

Abramson  DHDunkel  IJBrodie  SEKim  JWGobin  YP A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115 (8) 1398- 1404, 1404. e1
PubMed Link to Article
Brodie  SEPierre Gobin  YDunkel  IJKim  JWAbramson  DH Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol 2009;119 (1) 13- 22
PubMed Link to Article
Reese  ABHyman  GTapley  NForrest  AW The treatment of retinoblastoma by x-ray and triethylene melamine. AMA Arch Ophthalmol 1958;60 (5) 897- 906
PubMed Link to Article
Mohri  M The technique of selective ophthalmic arterial infusion for conservative treatment of recurrent retinoblastoma [in Japanese]. Keio J Med 1993;70679- 687
Yamane  TKaneko  AMohri  M The technique of ophthalmic artery infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004;9 (2) 69- 73
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,154 Views
40 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Care at the Close of Life: Evidence and Experience
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"

Care at the Close of Life: Evidence and Experience
Chemotherapy and Hormonal Therapy